Methods and compositions for cancer treatment
US-2024424094-A1 · Dec 26, 2024 · US
Treatment of carcinomas with a combination of EGF-pathway and telomerase inhibitors
US9155753B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9155753-B2 |
| Application number | US-53001408-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 6, 2008 |
| Priority date | Mar 9, 2007 |
| Publication date | Oct 13, 2015 |
| Grant date | Oct 13, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method and kit for inhibiting the proliferation of carcinoma cells are disclosed, based on a combination of an EGF pathway inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the antibody alone or the telomerase inhibitor alone.
First claim
Opening claim text (preview).
It is claimed: 1. A method for inhibiting the proliferation of carcinoma cells that express an EGF receptor, comprising (a) exposing the cells to an anti-EGF receptor antibody trastuzumab, and (b) either preceding, following, or concomitantly with step (a), exposing the cells to a telomerase inhibitor comprising an oligonucleotide which is characterized by: (i) N3′→P5′ thiophosphoramidate internucleoside linkages; (ii) comprising the sequence identified as SEQ ID NO: 12; and…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
- A61K31/7088Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
- A61K39/39558Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9155753B2 cover?
- A method and kit for inhibiting the proliferation of carcinoma cells are disclosed, based on a combination of an EGF pathway inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the antibody alone or the telomerase inhibitor alone.
- Who is the assignee on this patent?
- Tressler Robert J, Go Ning F, Geron Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K31/7088. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).